GE and Kohl's Are Among 2 Stocks Poised For Reversal

These names are showing bullish and bearish technical patterns over the past week.
Updated
Stocks quotes in this article: DVN, XEC, GE, AAOI, AWK, SO, KSS, VIPS, NKTR, COL

Below is a list of names for those charts we feel are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices. Bearish reversals imply institutional distribution and the potential for lower prices. Each group is listed by sector affiliation. Please feel free to contact the author for further details. (* denotes author has a long position in the name,**indicates the author has a short position in the name.)

Bullish Reversals:

Energy: Devon  (DVN) , Cimarex   (XEC)

Industrials: General Electric  (GE)

Technology: Applied Optoelectronics  (AAOI)

Utilities: American Water Works  (AWK) , Southern (SO)

Bearish Reversals:

Consumer Cyclical: Kohl's  (KSS) , Vipshop Holdings  (VIPS)

Healthcare: Nektar (NKTR)

Industrials: Rockwell Collins  (COL)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Action Alerts PLUS, which Jim Cramer co-manages as a charitable trust, was long KSS and XEC.

TAGS: Investing | U.S. Equity | Healthcare | Basic Materials | Consumer Discretionary | Stocks

More from Healthcare

Jim Cramer: Health Care Stocks, the Election and the Perfect Setup

Jim Cramer

Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.

Centene Could Decline Further as Broader Market Weakens

Bruce Kamich

Let's check the charts of the health plan provider.

Jim Cramer: I Don't See a Way Out of the Spiral Down Until We Have a Vaccine

Jim Cramer

We are back to square one except for one positive and one negative.

A 4.5% Dividend Stock Trading at a Healthy Discount

Bob Ciura

The stock is simply too cheap, given its strong results to begin 2020, and a highly profitable business model that generates huge amounts of cash flow.

Does Abbott Labs Still Pass My Test After Earnings?

Stephen Guilfoyle

Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight